Taurine

Phase 2Small molecule

TThird Military Medical University

Taurine is one of 64 small molecule programs targeting Cognitive Function. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive FunctionUnknown status

ExtremityUnknown status

CataractActive, not recruiting

Long COVIDNot yet recruiting

Cognitive FunctionPreclinical

Unknown status

ExtremityPreclinical

Unknown status

CataractPhase 2

Active, not recruiting

Long COVIDPreclinical

Not yet recruiting

Competition

Competitive Landscape

63 competitors in Cataract

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

3 2

Avelox

Bayer

Approved

3 3

Decadron

AAspen Global Incorporated

Approved

13 4

Bromday

BBausch Health Americas, Inc.

Approved

10 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

9 6

Lovenox

Sanofi

Approved

1 7

Toradol

Roche

Approved

1 8

Voltaren

Novartis

Approved

—9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 10

Cipro

Bayer

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Long COVID

NCT06721949

PreclinicalNot yet recruiting

Long COVID

NCT07682402

Clinical

Trials by Indication[1]

Long COVID2 trials

Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID

Recruiting·UUniversity of Alberta·Preclinical·NCT06721949·300 enrolled

An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes

Not yet recruiting·UUniversity of Alberta·Preclinical·NCT07682402·30 enrolled

Extremity1 trial

Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes

Unknown status·TThird Military Medical University·N/A·NCT03410537·200 enrolled

MPA1 trial

Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students

Completed·RRiyadh Colleges of Dentistry and Pharmacy·Phase 4·NCT02535143·60 enrolled

Oxidative Stress1 trial

Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT01192828·15 enrolled

Cataract1 trial

Taurine Eye Drops May Prevent the Progression of Cataract

Active, not recruiting·UUniversity Of Anbar·Phase 1/2·NCT06639711·50 enrolled

6 more indications

Bipolar Disorder1 trial

Taurine in Adolescents With Bipolar Disorder

Terminated·CCambridge Health Alliance·Phase 1·NCT00391001·4 enrolled

Double-blind1 trial

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

Completed·MMclean Hospital·Phase 2·NCT00217165·60 enrolled

Peripartum Cardiomyopathy1 trial

Taurine in Peripartum Cardiomyopathy

Completed·—·Phase 2/3·NCT03907267·40 enrolled

Psychosis1 trial

A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

Completed·MMelbourne Health·Phase 2/3·NCT00420823·121 enrolled

Cognitive Function1 trial

Taurine Supplementation on Cognitive Function in Patients With Diabetes

Unknown status·TThird Military Medical University·N/A·NCT03410173·200 enrolled

Unspecified2 trials

Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

Unknown status·HHamad Medical Corporation·Phase 1/2·NCT01226537·20 enrolled

Effect of Amnion Membrane With and Without Taurine on GCF TNF α Level.

Completed·MMaharishi Markendeswar University (Deemed to be University)·N/A·NCT04772508·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Taurine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taurine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taurine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Military Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThird Military Medical University

Taurine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Long COVID2 trials

Extremity1 trial

MPA1 trial

Oxidative Stress1 trial

Cataract1 trial

Bipolar Disorder1 trial

Double-blind1 trial

Peripartum Cardiomyopathy1 trial

Psychosis1 trial

Cognitive Function1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News